Core Viewpoint - The patent dispute between BeiGene and AbbVie regarding BTK inhibitors has reached a significant milestone, with the U.S. Patent and Trademark Office declaring AbbVie's Pharmacyclics' patent invalid, although an appeal is possible [1][3]. Group 1: Patent Dispute Details - The dispute began on June 13, 2023, when Pharmacyclics claimed that BeiGene's drug, Zebutinib, infringed on its patent for Ibrutinib [3]. - The U.S. Patent and Trademark Office's final decision on April 30, 2024, invalidated the entire rights of the '803 patent, which was under scrutiny [1][3]. - AbbVie has not yet responded regarding whether it will appeal the decision [1]. Group 2: Market Context - The global market for BTK inhibitors is projected to exceed 10 billion by 2024, with the U.S. being the largest market [7]. - As of 2024, Ibrutinib remains the top-selling BTK inhibitor, but its market share is being eroded by Zebutinib, which has shown significant growth [7]. - Ibrutinib's revenue is expected to decline by 6.9% in 2024, with U.S. sales dropping by 8.1% [7]. Group 3: Company Performance - BeiGene's Zebutinib is projected to achieve global sales of 2.6 billion in 2024, with U.S. sales reaching 2 billion, a 106.3% increase from the previous year [10]. - AstraZeneca's Acalabrutinib generated 3.129 billion in revenue in 2024, marking a 24% increase [13]. - The competitive landscape is intensifying, with multiple companies, including AbbVie, BeiGene, and Eli Lilly, having launched BTK inhibitors in the U.S. market [7]. Group 4: Ongoing Legal Issues - AbbVie has also filed a lawsuit against BeiGene for alleged theft of trade secrets related to BTK degraders, involving the compounds ABBV-101 and BGB-16673 [13]. - BeiGene asserts that its development of BGB-16673 predates AbbVie's patent application and is confident in its compliance with ethical standards [13].

Group 1 - The Dividend Aristocrats will underperform compared to the S&P 500 in April after three consecutive months of outperformance [1] - Year-to-date through March, the ProShares S&P 500 Dividend Aristocrat ETF (NOBL) increased by 3.11% [1]

Core Viewpoint - A class action securities lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. due to alleged securities fraud affecting investors during a specific time frame [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who sold or held shares of Cerevel from October 11, 2023, to August 1, 2024, and were affected by the alleged fraud [2]. - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering omitted critical information regarding AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [3]. - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially low price while possessing nonpublic information about AbbVie's acquisition interest, leading to a substantial profit when AbbVie announced the acquisition at $45 per share [3]. Group 2: Financial Implications - Bain Capital reportedly received over $120 million in windfall profits from shares acquired at the depressed offering price due to the alleged misinformation [3]. - Cerevel's January 18, 2024, Proxy statement is claimed to have misled investors regarding the nature and timing of AbbVie's interest in the company [3]. Group 3: Next Steps for Investors - Investors who suffered losses during the relevant period have until June 3, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without incurring out-of-pocket costs or fees [4]. Group 4: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].

Core Viewpoint - AbbVie Inc. (ABBV) is experiencing an upward trend in its stock price, gaining over 12% in the past week, but is now considered overbought, which may attract sellers and pressure the stock lower [1][2]. Group 1: Stock Performance - AbbVie has been trading higher, with a notable increase of more than 12% in the past week [1]. - The stock is currently classified as overbought, indicating that it has moved above its normal trading range [1]. Group 2: Market Dynamics - The concept of reversion to the mean suggests that an overbought stock like AbbVie may experience a downward movement, prompting some traders to sell in anticipation of this trend [2]. - The Relative Strength Index (RSI) is highlighted as a popular momentum indicator, with a default time period of 14 days, which currently shows neutral momentum for AbbVie [2][4]. Group 3: Technical Analysis - A 14-day RSI indicates that today's price is roughly the same as it was two weeks ago, not reflecting the recent rally [4]. - Adjusting the RSI time period from 14 to 5 days reveals that AbbVie shares are very overbought, suggesting a potential pause or end to the rally [5].

Core Insights - AbbVie has received FDA approval for RINVOQ (upadacitinib) as the first oral JAK inhibitor for treating giant cell arteritis (GCA) in adults, marking its ninth approved indication in the U.S. [1][2] - The approval is based on the successful results of the Phase 3 SELECT-GCA clinical trial, which demonstrated that 46.4% of patients on RINVOQ achieved sustained remission compared to 29.0% on placebo [2][6] - GCA is a significant autoimmune disease that can lead to severe complications, and the new treatment option aims to reduce reliance on glucocorticoids, which have substantial side effects [2][7] Company Overview - AbbVie is committed to addressing unmet needs in immune-mediated diseases, as highlighted by the introduction of RINVOQ for GCA [2][31] - The company has a strong focus on rheumatology, having developed multiple therapies for various autoimmune conditions [31][32] Clinical Trial Insights - The SELECT-GCA trial involved 428 patients and assessed the efficacy and safety of RINVOQ in combination with a corticosteroid taper regimen [6][2] - The trial's results support the potential for RINVOQ to provide sustained remission in GCA patients, which is a significant advancement in treatment options [2][6] Market Implications - The approval of RINVOQ for GCA expands AbbVie's portfolio in the rheumatology space, potentially increasing market share and revenue from this therapeutic area [1][2] - The introduction of RINVOQ may shift treatment paradigms for GCA, offering a new alternative to traditional glucocorticoid therapies [2][7]

Core Viewpoint - A class action securities lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. due to alleged securities fraud affecting investors during a specific time frame [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who sold or held shares of Cerevel from October 11, 2023, to August 1, 2024, and were impacted by the alleged fraud [2]. - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering omitted critical information regarding AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [3]. - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially low price while possessing nonpublic information about AbbVie's acquisition interest, leading to a substantial profit when AbbVie announced the acquisition at $45 per share [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant period have until June 3, 2025, to request to be appointed as lead plaintiff in the lawsuit [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [5].

Economic Data and Market Outlook - The upcoming week will see the release of significant economic data and corporate earnings, with a focus on the April non-farm payroll report and Q1 inflation data [1] - Economists expect Q1 GDP annualized growth to drop from 2.4% in Q4 to 0.1%, while the core PCE price index is projected to decrease from 2.8% to 2.5% year-on-year [1] - 180 S&P 500 companies will report quarterly earnings, with major tech firms like Apple, Amazon, Meta, and Microsoft being closely watched for their performance and guidance [1] Corporate Earnings and Sector Performance - AbbVie reported Q1 earnings that exceeded expectations, with global net revenue reaching $13.343 billion, a year-on-year increase of 8.4% [5] - The pharmaceutical sector is showing slightly positive sentiment, with companies like Johnson & Johnson and Merck also reporting stable earnings [5] - NXP Semiconductors reported Q1 revenue of $2.84 billion, a year-on-year decline of 9.3%, but adjusted earnings per share were above expectations [7] Industry Trends and Future Projections - The U.S. pharmaceutical sector is expected to see an annual revenue growth of 7.5% over the next three years, driven by an aging population and increasing prescription drug spending [6] - The demand for electric vehicles is projected to grow by 18%, while internal combustion vehicle demand is expected to decline by 7.2% [7] - The technology sector's revenue is anticipated to exceed $11 trillion by 2032, with an annual growth rate of 10% [10] Energy and AI Demand - Companies like Amazon and NVIDIA are exploring various energy sources to meet the growing energy demands of AI data centers, including natural gas and other fossil fuels [9] - There is a significant emphasis on the need for stable energy sources in the short term, despite long-term goals to reduce carbon emissions [9]

Core Viewpoint - AbbVie's stock price has seen a positive momentum following its first-quarter earnings report, outperforming the S&P 500 index due to bullish analyst notes [1]. Group 1: Analyst Recommendations - BMO Capital's analyst Evan David Seigerman maintained an "outperform" recommendation for AbbVie with a price target of $215 per share [2]. - HSBC highlighted AbbVie as a good value investment amidst downgrades of other healthcare stocks, indicating a positive outlook for the company [5]. Group 2: Earnings Performance - AbbVie's first-quarter earnings report showed strong performance, particularly from high-revenue products Skyrizi and Rinvoq, which compensated for expected declines in Humira sales [3]. - The company raised its per-share earnings guidance, which was viewed positively by analysts [4]. Group 3: Market Context - AbbVie's stock gained over 3% during the trading session, contrasting with the S&P 500's less than 0.1% gain, indicating strong investor confidence [1].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering, which may have impacted the stock price prior to a merger announcement with AbbVie Inc. [1][4] Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes shareholders who sold or held shares during this timeframe [3]. - Shareholders are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for June 3, 2025 [5]. Group 2: Allegations Against Cerevel - The complaint alleges that Cerevel's October 16, 2023 secondary stock offering omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [4]. - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share [4]. Group 3: Next Steps for Shareholders - Shareholders who register will be enrolled in a portfolio monitoring system to receive updates on the case [5]. - Participation in the class action has no cost or obligation for shareholders [5].

CONTACT US HERE: NEW YORK, April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ABBV during the timef ...